David Lawrence Selected Research

fevipiprant

12/2021	Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial.
5/2021	Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).
1/2021	Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Lawrence Research Topics

Disease

18	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 06/2010
17	Neoplasms (Cancer) 05/2020 - 03/2002
9	Mental Disorders (Mental Disorder) 01/2022 - 06/2011
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 07/2004
6	Asthma (Bronchial Asthma) 01/2022 - 01/2021
5	Lung Neoplasms (Lung Cancer) 01/2017 - 07/2004
5	Dyspnea (Shortness of Breath) 08/2015 - 12/2012
4	Nausea 01/2017 - 10/2009
4	Breast Neoplasms (Breast Cancer) 06/2010 - 03/2004
3	Myocardial Infarction 01/2022 - 11/2011
3	Fibrosis (Cirrhosis) 01/2017 - 03/2004
3	Headache (Headaches) 01/2017 - 01/2011
3	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2017 - 03/2011
3	Infections 02/2016 - 05/2010
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2011 - 12/2006
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2021 - 01/2020
2	Anxiety Disorders (Anxiety Disorder) 01/2020 - 06/2010
2	Cryptococcal Meningitis 10/2019 - 01/2019
2	Tuberculosis (Tuberculoses) 11/2018 - 05/2010
2	Disease Progression 01/2017 - 12/2006
2	Cataract (Cataracts) 11/2015 - 07/2011
2	Pulmonary Arterial Hypertension 11/2015 - 03/2013
2	Obesity 07/2015 - 07/2013
2	Pain (Aches) 07/2014 - 01/2013
2	Empyema 01/2012 - 05/2010
2	Carcinoma (Carcinomatosis) 11/2007 - 03/2002
1	Arrhythmogenic Right Ventricular Dysplasia (Arrhythmogenic Right Ventricular Cardiomyopathy) 05/2022
1	Heart Failure 05/2022
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 03/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	COVID-19 09/2021
1	Overweight 01/2021
1	Schizophrenia (Dementia Praecox) 01/2021
1	Esophageal Diseases 05/2020
1	Alcoholism (Alcohol Abuse) 01/2020
1	Immune Reconstitution Inflammatory Syndrome 10/2019
1	Mood Disorders (Mood Disorder) 03/2019
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2019
1	Lymphoma (Lymphomas) 11/2018

Drug/Important Bio-Agent (IBA)

17	indacaterolIBA 01/2022 - 06/2010
8	Varenicline (Chantix)FDA Link 01/2022 - 03/2011
7	Bronchodilator Agents (Bronchodilators)IBA 08/2015 - 06/2010
6	Tiotropium Bromide (Spiriva)FDA Link 08/2015 - 01/2011
4	Salmeterol Xinafoate (Serevent)FDA Link 01/2022 - 01/2011
4	SmokeIBA 01/2022 - 06/2010
4	Bupropion (Wellbutrin)FDA LinkGeneric 10/2021 - 06/2016
4	GoldIBA 08/2015 - 12/2012
3	prostaglandin D2 receptorIBA 12/2021 - 01/2021
3	fevipiprantIBA 12/2021 - 01/2021
3	Formoterol Fumarate (Oxis)FDA Link 02/2013 - 01/2011
3	Lenalidomide (CC 5013)FDA Link 05/2011 - 12/2006
2	Pharmaceutical PreparationsIBA 01/2022 - 12/2017
2	Prostaglandin D2IBA 12/2021 - 05/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 12/2011
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 10/2013
2	AntibodiesIBA 01/2017 - 01/2011
2	Immunoglobulin G (IgG)IBA 01/2016 - 04/2010
2	Imatinib Mesylate (Gleevec)FDA Link 11/2015 - 03/2013
2	Contrast MediaIBA 11/2013 - 07/2007
2	Messenger RNA (mRNA)IBA 10/2013 - 02/2004
2	Alkaline PhosphataseIBA 07/2012 - 01/2012
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2011 - 12/2008
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2008 - 07/2004
2	Carboplatin (JM8)FDA LinkGeneric 12/2008 - 07/2004
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2004 - 03/2002
2	LigandsIBA 07/2004 - 03/2002
2	Death Domain ReceptorsIBA 07/2004 - 03/2002
1	DesminIBA 05/2022
1	BenzodiazepinesIBA 03/2022
1	PalladiumIBA 01/2022
1	IridiumIBA 01/2022
1	Mometasone Furoate (Nasonex)FDA LinkGeneric 01/2022
1	Fluticasone (Cutivate)FDA LinkGeneric 01/2022
1	NitratesIBA 01/2022
1	Nicotine FDA Link 10/2021
1	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 05/2021
1	Prescription DrugsIBA 01/2021
1	Interleukin-1 (Interleukin 1)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Biological ProductsIBA 01/2020
1	Virulence Factors (Pathogenicity Factors)IBA 10/2019
1	liposomal amphotericin B FDA Link 01/2019
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2019

Therapy/Procedure

18	Therapeutics 05/2021 - 03/2002
8	Drug Therapy (Chemotherapy) 01/2021 - 03/2002
4	Radiotherapy 10/2018 - 03/2004
2	Nicotine Replacement Therapy 01/2022 - 01/2021
2	Length of Stay 09/2021 - 01/2012
2	Critical Care (Surgical Intensive Care) 09/2021 - 10/2017
2	Tobacco Use Cessation Devices 03/2019 - 06/2016
2	Extracorporeal Membrane Oxygenation 10/2017 - 08/2010
2	Conservative Treatment 01/2017 - 01/2014
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2016 - 06/2011
2	Medical Day Care (Partial Hospitalization) 11/2015 - 07/2011
1	Nebulizers and Vaporizers (Inhaler) 01/2022
1	Minimally Invasive Surgical Procedures 09/2021
1	Esophagectomy 05/2020
1	Aftercare (After-Treatment) 11/2018
1	Segmental Mastectomy (Lumpectomy) 11/2018